A 2026 study published in the Journal of the American Veterinary Medical Association (JAVMA) presents important new data supporting earlier dietary intervention. This large, retrospective analysis evaluated outcomes of 1,430 cats with early CKD, comparing those fed a therapeutic renal diet with those managed on non-renal diets.

Study Objective and Design

The primary objective of the study was to evaluate whether feeding a therapeutic renal diet to cats diagnosed with early CKD (IRIS stages 1 and 2) was associated with differences in disease progression and survival outcomes compared with cats not receiving a similar diet.

Methods

The investigators conducted a retrospective analysis of veterinary medical records from practices in the U.S. and Canada. Key features of the study design included:

• Inclusion of cats diagnosed with early-stage CKD (IRIS stage 1 or 2) based on creatinine, SDMA, urine specific gravity, and clinical assessment. The study broke stage 2 into substages: creatinine within the reference interval and creatinine above the reference level.
• Categorization into two cohorts:
  • Cats fed a renal diet that required veterinarian approval for purchase. Diets could be dry or wet, and some cats ate more than one brand.
  • Cats not fed a therapeutic renal diet (maintenance or other diets)
• Longitudinal follow-up to assess:
  • CKD progression to the next IRIS stage
  • Survival time
• Use of multivariable statistical modeling to adjust for confounding variables (e.g., age, baseline creatinine, comorbidities, body weight) and to estimate progression risk and mortality risk.

Key Findings

1. Reduced risk of CKD progression

Cats receiving a therapeutic renal diet had a significantly lower risk of CKD progression than untreated cats. This effect was observed in both IRIS stage 1 and stage 2 populations.

Statistical modeling showed that dietary therapy was independently associated with slower progression to higher IRIS stages, even after controlling for baseline disease severity and demographic factors.

This finding is particularly important because early-stage CKD often presents with subtle biochemical changes and limited clinical signs. Historically, some clinicians have delayed initiating a renal diet until stage 3. This study suggests that earlier intervention may alter the disease trajectory.

2. Improved survival outcomes

Survival time was significantly prolonged in cats with early CKD that ate a renal diet compared to those that did not.

• Treatment reduced the risk of all-cause mortality by 30% in the first 3 years after diagnosis.
• Treated cats that died during the study had a 20% longer survival time than untreated cats that died.

The study evaluated mortality from any cause, not exclusively renal causes. The survival benefits underscore the need to consider nutritional intervention for renal disease in all stages.

Notably, benefits were evident even in early-stage disease, reinforcing that nutrition therapy is not solely a late-stage or palliative measure.

Why Early Renal Diets May Influence Outcomes

Therapeutic renal diets are designed to address the metabolic abnormalities of CKD through multiple mechanisms:

• Controlled, high-quality protein intake to reduce nitrogenous waste while preserving lean body mass.
• Phosphorus restriction to mitigate secondary renal hyperparathyroidism and mineral bone disorder.
• Enhanced omega-3 fatty acid content to support anti-inflammatory pathways and renal perfusion.
• Increased caloric density to maintain body condition in cats with reduced appetite.
• Alkalinizing properties to address metabolic acidosis.

In early CKD, even mild hyperphosphatemia or a higher phosphorus load can damage nephrons and lead to ongoing fibrosis. Managing phosphorus intake and providing metabolic support early, before severe azotemia sets in, may help slow nephron loss.

Additionally, it is crucial to maintain nutritional status, as muscle wasting and weight loss serve as negative prognostic indicators in feline CKD. Early nutritional intervention can help preserve lean muscle, boost energy intake, and enhance overall resilience.

Clinical Implications for Practicing Veterinarians

1. Reconsider timing of dietary transition

Current IRIS recommendations include initiating a renal diet at IRIS stages 2–3. This study suggests there is value to introducing therapeutic renal nutrition at the diagnosis of stage 1 or early stage 2 CKD.

For clinicians, this shifts the discussion from “later supportive care” to “early disease-modifying intervention.”

2. Diagnostic test findings become more actionable earlier

Earlier nutritional intervention supports broader use of sensitive biomarkers such as SDMA, routine senior screening panels, and closer monitoring of trends of creatinine and other renal parameters. This also includes testing such as urinalysis, urine specific gravity, and urine protein:creatinine ratio to look for early renal dysfunction and proteinuria. Routine blood pressure measurement is also encouraged.

3. Owner counseling becomes evidence-based

One of the most common challenges in early CKD management is client resistance to dietary changes in a cat without clinical signs. Owners may think:

• “Is this really necessary right now?”
• “She seems perfectly fine.”

This research enables clinicians to offer counseling based on data insights:

• Reduced risk of disease progression
• Clear evidence of a survival benefit
• Benefits observed even in early-stage disease

Presenting the diet as a proactive approach to preserving quantity of life, rather than just a reactive solution, could enhance compliance.

4. Integrating with comprehensive CKD management

Dietary therapy remains the cornerstone of CKD management and complements:

• Blood pressure monitoring and management
• Phosphate binders (when indicated)
• Potassium supplementation
• Monitoring of SDMA, creatinine, phosphorus, and body condition

This new evidence reinforces the view that nutritional therapy should be considered with continued patient monitoring.

Practical Takeaways for the Exam Room

For clinicians managing feline CKD:

1. Consider initiating a therapeutic renal diet at IRIS stage 1 or early stage 2 with appropriate monitoring of phosphorus and FGF-23.
2. Encourage earlier diagnostic testing that includes biomarker screening such as SDMA; trending of creatinine and other renal blood values; complete urinalysis; and urine protein:creatinine ratio.
3. Emphasize phosphorus control, supporting electrolyte and acid-base balance, and moderate, high-quality protein intake as disease-modifying strategies.
4. Monitor body weight and muscle condition closely to assess whether nutritional needs are being met.
5. Frequently screen blood pressure for any developing hypertension.

Transition strategies should remain gradual and individualized, especially for cats with strong dietary preferences. Palatability trials and mixed-feeding protocols may improve acceptance.

From Supportive Care to Standard of Care

The 2026 AVMA study provides meaningful, practice-relevant evidence that therapeutic renal diets confer measurable benefits for cats with early CKD. Cats fed a renal diet had a significantly lower risk of disease progression and longer median survival than untreated cats.

For veterinarians, these findings reinforce a critical message: Nutritional therapy should begin early, not late. By incorporating therapeutic renal nutrition at the earliest stages of CKD, practitioners can counsel owners more confidently, support metabolic health, and potentially extend both lifespan and quality of life.

Early dietary intervention is now backed by real-world outcome data, moving beyond just a theoretical recommendation.